2024
Provider Experience With the Use of Ketamine for Refractory Status Epilepticus
Tantillo G, Davis N, Granstein J, Yoo J, Agarwal P, Reilly K, Reynolds A, Kayal G, Liang J, Jetté N. Provider Experience With the Use of Ketamine for Refractory Status Epilepticus. Clinical Neuropharmacology 2024, 47: 37-43. PMID: 38478363, DOI: 10.1097/wnf.0000000000000582.Peer-Reviewed Original ResearchConceptsRefractory status epilepticusStatus epilepticusPerceived contraindicationsUse of vasopressorsFirst-line agentsRefractory status epilepticus treatmentSecond-line agentsAssociated with complicationsElevated intracranial pressureNeurocritical Care SocietyRespiratory depressionHeart failureEEG monitoringHemodynamic supportOptimal doseKetamine useSeizure controlIntracranial pressureControl seizuresDecreased needKetamine usersAmerican Epilepsy SocietyKetamineAmerican AcademyAnesthetic agents
2016
A Quality of Care Analysis Utilizing the 2014 American Academy of Neurology Updated Quality Measurement Set for Patients with Epilepsy (P1.067)
Lai G, Wolf S, McGoldrick P, Lee K, Gao W, Yoo J, Kepecs M, Harden C. A Quality of Care Analysis Utilizing the 2014 American Academy of Neurology Updated Quality Measurement Set for Patients with Epilepsy (P1.067). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p1.067.Peer-Reviewed Original Research